- US11820760utility2023Crystalline Polymorphs of Bruton's Tyrosine Kinase Inhibitors0 cites
- US11814362utility2023ASK1 Inhibiting Agents0 cites
- US11781135utility2023Methods for Treating Alzheimer's Disease0 cites
- US11753668utility2023Copper Supplementation for Control of Glycosylation in Mammalian Cell Culture Process0 cites
- US11697670utility2023Methods for Purifying Antibodies Having Reduced High Molecular Weight Aggregates0 cites
- US11699506utility2023Method for Distribution of a Drug0 cites
- US11686734utility2023Methods and Products for Evaluating an Immune Response to a Therapeutic Protein0 cites
- US11660054utility2023Medical Diagnostic and Treatment Systems and Their Methods of Use0 cites
- US11655289utility2023Pharmaceutical Compositions Containing Anti-beta Amyloid Antibodies0 cites
- US11602530utility2023CRM1 Inhibitors for Treating Epilepsy0 cites
- US11591595utility2023Compositions for Modulating Tau Expression0 cites
- US11571477utility2023Anti-vla-4 Antibodies0 cites
- US11572356utility2023Biaryl Inhibitors of Bruton's Tyrosine Kinase0 cites
← PreviousPage 3 of 3